Stay updated on SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.3%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.3%
- Check16 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and country listings. These changes enhance the clarity and relevance of the page's content.SummaryDifference100%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check45 days agoChange DetectedThe webpage has been updated to include new information about a clinical trial for non-small cell lung cancer, including its title, sponsor, and last update date. Additionally, the page emphasizes that the U.S. government does not review or approve all studies listed.SummaryDifference81%
Stay in the know with updates to SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.